ACM
BCYC

Aquilo Capital Management’s Bicycle Therapeutics BCYC Stock Holding History

Aquilo Capital Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-171,695
Closed -$1.46M – 5
2025
Q1 		$1.46M Sell
171,695
-50,216
-23% -$592K 2.61% 10
2024
Q4 		$3.11M Buy
221,911
+40,000
+22% +$857K 4.68% 6
2024
Q3 		$4.12M Buy
181,911
+25,219
+16% +$582K 3.12% 9
2024
Q2 		$3.17M Buy
+156,692
New +$3.54M 3.06% 9
2019
Q4 		– Sell
-767,026
Closed -$8.74M – 13
2019
Q3 		$8.74M Buy
767,026
+29,497
+4% +$253K 6.15% 7
2019
Q2 		$7.42M Buy
+737,529
New +$8.89M 2.58% 10

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Aquilo Capital Management's BCYC Position: Q2 2025 in Review

Aquilo Capital Management sold out of Bicycle Therapeutics (BCYC) in Q2 2025, closing a stake of 171,695 shares — an estimated $1.46M sold.

Aquilo Capital Management first reported a position in BCYC in Q2 2019 and held it in 6 quarters. The position peaked at $8.74M in Q3 2019. 110 funds tracked by Wall St. Rank hold BCYC as of Q2 2025.

  • Aquilo Capital Management reported no remaining Bicycle Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Aquilo Capital Management sold 171,695 Bicycle Therapeutics shares in Q2 2025, an estimated $1.46M.
  • Aquilo Capital Management first reported a position in Bicycle Therapeutics in Q2 2019 and held it in 6 quarters.
  • Aquilo Capital Management's Bicycle Therapeutics position peaked at $8.74M in Q3 2019.
  • 110 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2025.

Based on Aquilo Capital Management's 13F filing for Q2 2025.